From the sunbaked wastes of Arizona's Navajo Reservation came dramatic news about the new TB drug, isoniazid (TIME, March 3). The report was carefully evaluated in the gleaming tower of Manhattan's New York Hospital-Cornell Medical Center. Then, last week, Cornell's Dr. Ralph Tompsett got up in London's cavernous, dingy Central Hall and passed the news to 400-odd experts gathered for a British Empire conference on TB. Sum of the findings: isoniazid is the only drug that belongs in the same class with streptomycin for effectiveness against tuberculosis. In most respects it is as...
To continue reading:
or
Log-In
